Kidney cancer accounts for 63% of cancers that affect the elderly and access to innovative therapies are needed to diagnose and treatment. So this study was conducted with the aim to find out the type of better therapy in renal cancer in elderly. This study was conducted on 21 cases of renal cell cancer in first group and 64 cases in group II . Use of humanized monoclonal antibodies administered at a dose of 10 mg / kg in combination with the alpha allIFN 9 (MUI) dose subcutaneously three times a week for three months with a positive response at 12 months in 91% of cases. AC of the kidney is a typical disease of geriatric and the prognosis is greatly influenced by other underlying conditions, surgery is the treatment of choice healing while finding difficulty in implementing patient with: renal insufficiency, solitary kidney, or in 30% of cases (occasional) in late-stage cancers. the chemotherapy used in association to IFN led to a partial response in the progression of the disease 15% of cases. Results show that in these cases treated with this therapy had encouraging results in terms of complete response, partial response and stable disease. Disappointing results reported (chemo, radio,) in this study have led to the use of biological response modifiers establishing itself as the treatment of choice (first results) in advanced kidney cancer, in combination with lIFN 2alfa. Additional molecular biology studies are useful for better understanding of the mechanisms that regulate the aging process and the onset of illness in old age.
Treatment Therapies in Renal Cell Carcinoma in elderly: A Descriptive Analysis
Graziano, Antonino;
2016-01-01
Abstract
Kidney cancer accounts for 63% of cancers that affect the elderly and access to innovative therapies are needed to diagnose and treatment. So this study was conducted with the aim to find out the type of better therapy in renal cancer in elderly. This study was conducted on 21 cases of renal cell cancer in first group and 64 cases in group II . Use of humanized monoclonal antibodies administered at a dose of 10 mg / kg in combination with the alpha allIFN 9 (MUI) dose subcutaneously three times a week for three months with a positive response at 12 months in 91% of cases. AC of the kidney is a typical disease of geriatric and the prognosis is greatly influenced by other underlying conditions, surgery is the treatment of choice healing while finding difficulty in implementing patient with: renal insufficiency, solitary kidney, or in 30% of cases (occasional) in late-stage cancers. the chemotherapy used in association to IFN led to a partial response in the progression of the disease 15% of cases. Results show that in these cases treated with this therapy had encouraging results in terms of complete response, partial response and stable disease. Disappointing results reported (chemo, radio,) in this study have led to the use of biological response modifiers establishing itself as the treatment of choice (first results) in advanced kidney cancer, in combination with lIFN 2alfa. Additional molecular biology studies are useful for better understanding of the mechanisms that regulate the aging process and the onset of illness in old age.File | Dimensione | Formato | |
---|---|---|---|
IMJH-MAY-2016-5-Treatment Therapies in Renal Cell Carcinoma.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Dimensione
395.24 kB
Formato
Adobe PDF
|
395.24 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.